Moxonidine Effects on Neuropeptide Y

Obesity Clinical Trial

Official title:

Effects of Moxonidine Administration on Serum Neuropeptide Y Levels in Hypertensive Individuals: A Prospective Observational Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05147753
• Other study ID #: 7337_20042021
• Status: Completed
• Phase: Phase 4
• Start date: January 11, 2010
• Est. completion date: June 30, 2014

Study information

• Verified date: November 2021
• Source: Aristotle University Of Thessaloniki
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Treatment with monotherapy of moxonidine 0.6 mg daily in treatment-naïve subjects with mild or moderate hypertension

Description:

Treatment with 0.6 mg moxonidine daily in treatment-naïve subjects with mild or moderate hypertension according to guidelines (Stage 1: Systolic Blood Pressure =140-159 mmHg, Diastolic Blood Pressure =90-99 mmHg, and Stage 2: systolic blood pressure=160-179 mmHg, diastolic blood pressure=100-109 mmHg) that require monotherapy and reevaluation after 12 weeks

Recruitment information / eligibility

• Status: Completed
• Enrollment: 90
• Est. completion date: June 30, 2014
• Est. primary completion date: June 30, 2014
• Accepts healthy volunteers: No
• Gender: All
• Age group: 25 Years to 75 Years

Eligibility

Inclusion Criteria:

• treatment-naïve subjects with mild or moderate hypertension according to Joint National Committee 7 and European Society Hypertension / European Society Cardiology 2008 (Stage 1: Systolic Blood Pressure =140-159 mmHg, Diastolic Blood Pressure =90-99 mmHg, and Stage 2: Systolic=160-179 mmHg, Diastolic=100-109 mmHg) that require monotherapy

Exclusion Criteria:

• age beyond 25-75 years,

• not taking currently anti-hypertensive medication

• not taking anti-diabetic or lipid lowering medication and other diseases or conditions that may influence blood pressure, heart rate and catecholamines' and Neuropeptide Y levels, including anemia, fever, stage III hypertension, coronary artery disease, recent (less than 6 months) myocardial infraction or stroke, heart failure, secondary hypertension, diabetes mellitus, abnormal thyroid status or other obesity-related endocrinopathies, pregnancy, kidney failure, alcohol abuse, malignancies, depression or other psychiatric illnesses, such as schizophrenia,

Related Conditions & MeSH terms

• Hypertension
• Obesity

Intervention

Drug:
• Moxonidine
0.6 mg moxonidine daily

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Aristotle University Of Thessaloniki

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	serum Neuropeptide Y levels	ELISA	12 weeks
Primary	systolic blood pressure	mmHg	12 weeks
Primary	diastolic blood pressure	mmHg	12 weeks
Secondary	Weight	kg	12 weeks
Secondary	Body Mass Index	kg/m2	12 weeks
Secondary	Total Cholesterol	mg/dl	12 weeks
Secondary	HDL Cholesterol	mg/dl	12 weeks
Secondary	LDL Cholesterol	mg/dl	12 weeks
Secondary	Serum triglycerides	mg/dl	12 weeks